Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BRKR declined for three days, in 234 of 317 cases, the price declined further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BRKR as a result. In 67 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for BRKR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 27 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
BRKR moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for BRKR crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 201 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
BRKR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.049) is normal, around the industry mean (10.930). P/E Ratio (74.885) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.052). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
WAT saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 68 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 73%.
The 10-day RSI Indicator for WAT moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 23 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for WAT turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 28 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
WAT broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 173 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.864) is normal, around the industry mean (72.578). P/E Ratio (112.137) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
BRKR | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 91 | |
SMR RATING 1..100 | 92 | 89 | |
PRICE GROWTH RATING 1..100 | 39 | 21 | |
P/E GROWTH RATING 1..100 | 5 | 3 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (59) in the Medical Specialties industry is in the same range as WAT (74). This means that BRKR’s stock grew similarly to WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (91) in the Medical Specialties industry is in the same range as BRKR (100). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's SMR Rating (89) in the Medical Specialties industry is in the same range as BRKR (92). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's Price Growth Rating (21) in the Medical Specialties industry is in the same range as BRKR (39). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
WAT's P/E Growth Rating (3) in the Medical Specialties industry is in the same range as BRKR (5). This means that WAT’s stock grew similarly to BRKR’s over the last 12 months.
| BRKR | WAT | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 64% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 63% |
| Advances ODDS (%) | 10 days ago 69% | 16 days ago 62% |
| Declines ODDS (%) | 1 day ago 74% | 1 day ago 63% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 62% |
| Aroon ODDS (%) | N/A | 1 day ago 57% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 2 bullish TA indicator(s).
BRKR (@Medical/Nursing Services) experienced а -7.12% price change this week, while WAT (@Medical Specialties) price change was -1.66% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.54%. For the same industry, the average monthly price growth was -6.26%, and the average quarterly price growth was -14.18%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.55%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +36.12%.
BRKR is expected to report earnings on Oct 29, 2026.
WAT is expected to report earnings on Nov 03, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-2.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with BRKRP. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then BRKRP could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -0.11% | ||
| BRKRP - BRKR | 91% Closely correlated | -0.19% | ||
| A - BRKR | 78% Closely correlated | +0.16% | ||
| MTD - BRKR | 75% Closely correlated | +2.24% | ||
| WAT - BRKR | 68% Closely correlated | -0.68% | ||
| RVTY - BRKR | 68% Closely correlated | -0.34% | ||
More | ||||
A.I.dvisor indicates that over the last year, WAT has been loosely correlated with A. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.68% | ||
| A - WAT | 65% Loosely correlated | +0.16% | ||
| RVTY - WAT | 60% Loosely correlated | -0.34% | ||
| BRKR - WAT | 58% Loosely correlated | -0.11% | ||
| CRL - WAT | 57% Loosely correlated | -0.94% | ||
| TMO - WAT | 56% Loosely correlated | +0.12% | ||
More | ||||